Utsugisawa K - Search Results

1

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Among authors: utsugisawa k. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.

2

[In situ expression of IL-1 beta and IL-2 mRNA in thymuses from patients with myasthenia gravis].

Utsugisawa K, Yamagata M, Saitho K, Kawamorita A, Tohgi H. Utsugisawa K, et al. Rinsho Shinkeigaku. 1994 May;34(5):449-53. Rinsho Shinkeigaku. 1994. PMID: 7924056 Japanese.

3

Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis.

Utsugisawa K, Nagane Y, Obara D, Kondoh R, Yonezawa H, Tohgi H. Utsugisawa K, et al. Eur Neurol. 2003;49(3):160-3. doi: 10.1159/000069079. Eur Neurol. 2003. PMID: 12646760

4

Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study.

Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Nagane Y, et al. Among authors: utsugisawa k. Eur Neurol. 2005;53(3):146-50. doi: 10.1159/000085833. Epub 2005 May 17. Eur Neurol. 2005. PMID: 15900097 Clinical Trial.

5

Perivascular infiltrate of memory lymphocytes and mature dendritic cells in MG thymomas.

Nagane Y, Utsugisawa K, Akutsu H, Sato Y, Terayama Y. Nagane Y, et al. Among authors: utsugisawa k. Neurology. 2005 Sep 13;65(5):770-2. doi: 10.1212/01.wnl.0000174560.35190.84. Neurology. 2005. PMID: 16157920

6

Classification of myasthenia gravis based on autoantibody status.

Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Terayama Y, Suzuki N, Kuwana M. Suzuki S, et al. Among authors: utsugisawa k. Arch Neurol. 2007 Aug;64(8):1121-4. doi: 10.1001/archneur.64.8.1121. Arch Neurol. 2007. PMID: 17698702

7

Monitoring treatment with cyclosporine microemulsion in myasthenia gravis.

Utsugisawa K, Nagane Y, Suzuki S, Suzuki N. Utsugisawa K, et al. Eur J Neurol. 2008 Jun;15(6):598-604. doi: 10.1111/j.1468-1331.2008.02130.x. Epub 2008 Apr 9. Eur J Neurol. 2008. PMID: 18410372

8

Factors associated with response to calcineurin inhibitors in myasthenia gravis.

Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Nagane Y, et al. Among authors: utsugisawa k. Muscle Nerve. 2010 Feb;41(2):212-8. doi: 10.1002/mus.21462. Muscle Nerve. 2010. PMID: 19816912

9

Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients.

Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Nagane Y, et al. Among authors: utsugisawa k. Eur Neurol. 2010;64(3):186-90. doi: 10.1159/000319172. Epub 2010 Aug 17. Eur Neurol. 2010. PMID: 20720424 Clinical Trial.

10

Early aggressive treatment strategy against myasthenia gravis.

Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Nagane Y, et al. Among authors: utsugisawa k. Eur Neurol. 2011;65(1):16-22. doi: 10.1159/000322497. Epub 2010 Nov 30. Eur Neurol. 2011. PMID: 21116111

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters